Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ABEO vs BZFD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABEO Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

ABEO Overall Winner 6-Pillar Tally: ABEO 3 – 3 BZFD Matrix Metrics: ABEO 7 – 3 BZFD

As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over BuzzFeed, Inc. (BZFD) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ABEO carries a Unified Composite Score of 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin), whereas BZFD carries 51.3/100 (HOLD) at $0.38 (N/M Forward P/E, -17.7% operating margin).

  • Composite vs. Pillar Nuance: While BZFD currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. ABEO 49.9/100 HOLD), ABEO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-186.1% vs. -17.7% operating margin) and revenue trajectory (+2745.0% vs. -43.8% YoY).
  • Technical & Structure Timing Caution: ABEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6); meanwhile BZFD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABEO vs BZFD
ABEO NASDAQ Head-to-Head Winner
Abeona Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.42
-1.22% 1D
Market Cap $167.4M
TTM Revenue $39M
Forward P/E 18.7x
Beta / 30D Vol 0.60β · 149% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 60.0 Fund 61.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.9%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $3.39 · SMA50: $4.38
BZFD NASDAQ
BuzzFeed, Inc. Class A Common Stock
Communications Services, Nec
$0.38
+2.79% 1D
Market Cap $38.1M
TTM Revenue $150M
Forward P/E N/M
Beta / 30D Vol 2.52β · 192% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 55.0 Fund 52.0 Flow 60.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 25
RSI-14: 25.3 · SMA20: $0.65 · SMA50: $0.91

6-Pillar Scorecard Institutional Category Breakdown (ABEO 3 – 3 BZFD)

Columns: Metric · ABEO · BZFD
1. Valuation Multiples ABEO
Forward P/E 18.7x N/M
Trailing P/E 18.7x N/M
PEG Ratio N/M N/M
EV / Revenue 3.0x 0.5x
2. Growth & Scale ABEO
Revenue Growth (YoY) +2745.0% -43.8%
Earnings Growth (YoY) +0.0% -54.7%
TTM Revenue (USD) $39M $150M
Market Cap $167.4M $38.1M
3. Profitability & Quality BZFD
Gross Margin -3.5% 40.5%
Operating Margin -186.1% -17.7%
Net Profit Margin -160.3% -48.0%
Return on Equity (ROE) -42.1% -123.0%
4. Balance Sheet & Cash Flow BZFD
Cash Generation (TTM) -$66M -$39M
Cash Flow Margin N/A -26.2%
Net Cash / Leverage $50M Net Cash $39M Net Debt (1.18x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABEO
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 165.8% (27th %ile) 319.8% (50th %ile)
Put/Call OI Skew 0.26x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BZFD
OpEx & R&D Intensity N/A 58.2% of Rev ($88M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Internet Content & Information Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABEO (7) vs BZFD (3)
Institutional Metric ABEO BZFD Criterion Row Edge
Market Capitalization
Scale
$167.4M $38.1M Larger Scale ABEO
Trailing P/E Ratio
Valuation
18.7x N/M Lower Multiple ABEO
Forward P/E Ratio
Valuation
18.7x N/M Lower Multiple ABEO
Revenue Growth (YoY)
Growth
+2745.0% -43.8% Higher Growth ABEO
Operating Margin (TTM)
Profitability
-186.1% -17.7% Higher Margin BZFD
Net Profit Margin
Profitability
-160.3% -48.0% Higher Margin BZFD
Return on Equity (ROE)
Capital Efficiency
-42.1% -123.0% Higher ROE ABEO
52-Week Range Position
Momentum
6% ($2–$8) 2% ($0–$2) Stronger Trend ABEO
Beta / 30D Volatility
Risk Regime
0.60β · 149% Vol 2.52β · 192% Vol Lower Realized Risk ABEO
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite BZFD
Trailing 12M Revenue (USD)
Operating Scale
$39M $150M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-3.5% 40.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.0x EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M ($50M Net Cash) -$39M ($39M Net Debt (1.18x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABEO +15.45 pp
ABEO: -45.86% · BZFD: -61.31%
3M Horizon ABEO +6.72 pp
ABEO: -60.07% · BZFD: -66.79%
6M Horizon ABEO +26.53 pp
ABEO: -55.51% · BZFD: -82.04%
1Y Horizon ABEO +17.63 pp
ABEO: -42.38% · BZFD: -60.01%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ABEO Revenue BZFD Revenue ABEO Op. Margin BZFD Op. Margin Margin Leader
FY2018 $0M N/A -1940.2% N/A ABEO
FY2019 N/A $320M N/A -12.7% BZFD
FY2020 $10M $320M -814.2% 3.8% BZFD
FY2021 $0M $380M -2994.5% -6.2% BZFD
FY2022 $0M $330M -3600.8% -35.2% BZFD
FY2023 $0M $230M -1346.7% -19.5% BZFD
FY2024 N/A $190M N/A -12.4% BZFD
FY2025 $10M $190M -1536.9% -25.8% BZFD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABEO BREAKDOWN
71d in phase · OBV NEUTRAL
Current IV 165.8%
IV Percentile 27th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BZFD BREAKDOWN
126d in phase · OBV NEUTRAL
Current IV 319.8%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BZFD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABEO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $167.4M market capitalization and -186.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BZFD Moat Profile Cyclical / Execution-Driven Positioning
Internet Content & Information Operator
Competes within the Internet Content & Information value chain with $38.1M market capitalization and -17.7% operating margin.
OpEx & R&D Reinvestment 58.2% of Rev ($88M)
90D Engineering Disclosures 0 Published

Investor FAQ ABEO vs BZFD Key Questions & Quantitative Answers

As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over BuzzFeed, Inc. (BZFD) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ABEO carries a Unified Composite Score of 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin), whereas BZFD carries 51.3/100 (HOLD) at $0.38 (N/M Forward P/E, -17.7% operating margin). Composite vs. Pillar Nuance: While BZFD currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. ABEO 49.9/100 HOLD), ABEO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-186.1% vs. -17.7% operating margin) and revenue trajectory (+2745.0% vs. -43.8% YoY). Technical & Structure Timing Caution: ABEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6); meanwhile BZFD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABEO leads the Growth & Scale pillar: ABEO posts +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin), compared with BZFD at -43.8% YoY revenue growth and -54.7% YoY earnings growth on $150M TTM revenue (40.5% gross margin, -17.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ABEO cumulative revenue shifted +0.0% while BZFD shifted -40.6%. In operating R&D and SG&A reinvestment, ABEO deploys N/A (0 90-day corporate R&D disclosures) versus 58.2% of Rev ($88M) (0 disclosures) for BZFD.

ABEO screens cheaper on headline valuation multiples. ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 3.0x EV/Revenue (unreported FCF margin), whereas BZFD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-26.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABEO (-42.1% ROE) versus BZFD (-123.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk). By comparison, BZFD carries 319.8% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.52β · 192% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.